Hold control (command on a Mac) and press the + key as many times as necessary to increase the font size.
Hold control (command on a Mac) and press the - key to reduce the font size. - hide
Online Bulletin Board Support Group Users: click "Forum" to view archives and post messages. - hide
Show/Hide

Save the Dates - Patient Education Events Coming in Baltimore and Boston!

Oct. 8, 2017

Save the dates - the GDATF is headed to the East Coast this fall to host two patient education events

Baltimore: Sunday, Oct. 8th (during the THYCA annual meeting for thyroid cancer survivors).
Boston: Saturday, Oct. 14th (co-hosted by Massachusetts Eye and Ear).

Info on registration, times, and presenters will be coming soon!

Read More

  • Save the Dates - Patient Education Events Coming in Baltimore and Boston!

    Oct. 8, 2017

    Save the dates - the GDATF is headed to the East Coast this fall to host two patient education events

    Baltimore: Sunday, Oct. 8th (during the THYCA annual meeting for thyroid cancer survivors).
    Boston: Saturday, Oct. 14th (co-hosted by Massachusetts Eye and Ear).

    Info on registration, times, and presenters will be coming soon!

    Read More

  • Thyroid Eye Disease Breakthrough!

    June 30, 2017

    If you've been diagnosed with thyroid eye disease, you know that the current options leave much to be desired: wait, wait, wait, wait some more -- and eventually get approved for one or more surgeries to address bulging, swelling, and double vision. (With steroid therapy sometimes used as a temporary stopgap).  However, the successful trial of a brand new drug could prove to be a game-changer for patients living with this disfiguring and frustrating condition ...

    Read More

  • Wilmer Eye Institute Thyroid Eye Disease Study

    June 30, 2017

    The Johns Hopkins Wilmer Eye Institute is currently recruiting patients for a new clinical study using celecoxib (Celebrex), a non-steroidal anti-inflammatory drug approved by the Food and Drug Administration (FDA) for the treatment of pain, osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as a treatment for active thyroid eye disease (TED).  The study is intended to evaluate the efficacy of COX-2 inhibition in the treatment of active TED and its ability to improve both the acute ...

    Read More

  • Recent Forum Posts

Questions? Problems? Please contact us at info@ngdf.org or 877-643-3123.

GDATF on Facebook
Thank you to our Diamond Sponsors:
Quidel-Thyretain The Bell Charitable Foundation

Support the GDATF and become a member today!

© 2017 Graves' Disease & Thyroid Foundation